Cabaletta Bio is trading at $2.62, declining -10.14% alongside weaker biotech sentiment and a 2.11% drop in the XBI biotech ETF.
- The move follows disappointing Ionis Pharmaceuticals pelacarsen trial results and broader biotech downgrades.
- No new company-specific announcement or direct catalyst was identified for September 15, 2026; the move appears primarily sector-led.
- Broad markets are also lower, reinforcing the defensive risk-off backdrop.